tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Apr 25;28(7).
doi: 10.3201/eid2807.220127. Online ahead of print.
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Toshihiro Sato, Shinjiro Kodama, Keizo Kaneko, Junta Imai, Hideki Katagiri
Abstract
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Keywords: COVID-19; Japan; SARS-CoV-2; coronavirus disease; coronaviruses; immune checkpoint inhibitor; mRNA vaccine; nivolumab; respiratory infections; second SARS-CoV-2 vaccination; severe acute respiratory syndrome coronavirus 2; type 1 diabetes mellitus; vaccines; virus; zoonoses.
. 2022 Apr 25;28(7).
doi: 10.3201/eid2807.220127. Online ahead of print.
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Toshihiro Sato, Shinjiro Kodama, Keizo Kaneko, Junta Imai, Hideki Katagiri
- PMID: 35468049
- DOI: 10.3201/eid2807.220127
Abstract
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Keywords: COVID-19; Japan; SARS-CoV-2; coronavirus disease; coronaviruses; immune checkpoint inhibitor; mRNA vaccine; nivolumab; respiratory infections; second SARS-CoV-2 vaccination; severe acute respiratory syndrome coronavirus 2; type 1 diabetes mellitus; vaccines; virus; zoonoses.